登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Spike S1 >S1N-C52Hz

SARS-CoV-2 Spike S1 Protein, His Tag (BA.2.75/Omicron)

分子别名(Synonym)

Spike,S1 protein,Spike glycoprotein Subunit1,S glycoprotein Subunit1,Spike protein S1

表达区间及表达系统(Source)

SARS-CoV-2 Spike S1, His Tag (BA.2.75/Omicron) (S1N-C52Hz) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Arg 685 (Accession # QHD43416.1 (T19I, LPP24-26del, A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H)). The spike mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: BA.2.75).

Predicted N-terminus: Val 16

Request for sequence

蛋白结构(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 76.8 kDa. The protein migrates as 110-130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Spike S1 SDS-PAGE

SARS-CoV-2 Spike S1, His Tag (BA.2.75/Omicron) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Spike S1 ELISA

Immobilized SARS-CoV-2 Spike S1, His Tag (BA.2.75/Omicron) (Cat. No. S1N-C52Hz) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (Cat. No. SPD-M265) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

Spike S1 ELISA

Immobilized SARS-CoV-2 Spike S1, His Tag (BA.2.75/Omicron) (Cat. No. S1N-C52Hz) at 2 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 1-31 ng/mL (Routinely tested).

Protocol

Spike S1 ELISA

Immobilized SARS-CoV-2 Spike S1, His Tag (BA.2.75/Omicron) (Cat. No. S1N-C52Hz) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.4-25 ng/mL (Routinely tested).

Protocol

 
评论(0)
  1. 136XXXXXXX0
  2. 0人赞
  3. 购买该蛋白作为噬菌体库筛选抗原使用,该蛋白Biotin稳定,可以很好地与磁珠和目标抗体结合,已经得到很好的筛选结果。
  4. >
  5. 2022-10-28
  1. 176XXXXXXX0
  2. 0人赞
  3. 从技术服务知道了这家公司,我们在多项目上委托了BLI服务,服务体验很好,数据及报告做的很漂亮。后续就从百普赛斯直接购买了蛋白,实验数据稳定,蛋白纯度及实验响应比较出色,供货稳定。成为了我们的关键试剂。
  4. 2022-9-5
  1. 156XXXXXXX8
  2. 0人赞
  3. 我们采购该蛋白用于检测自主开发的抗TROP-2抗体的亲和力,通过OCTET检测其亲和动力学,我们用已经获批的IMMU132进行了测试,其亲和动力学常数为nM级别(1.05nM)。
  4. 2022-4-6
 
ACRO质量管理体系
 
 

背景(Background)

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

 

前沿进展

Advances in antibody-drug conjugates for endometrial cancer
Tu, Li, Zou et al
Mol Cancer Ther (2025)
Abstract: The treatment of advanced endometrial cancer is clinically challenging, prompting the exploration of innovative therapeutic strategies such as antibody-drug conjugates (ADCs). ADCs, which include monoclonal antibodies, cytotoxic components, and linkers, demonstrate robust targeting, cytotoxicity, and manageable adverse effects. To provide a thorough understanding of the status of research, this review elucidates promising therapeutic targets in endometrial cancer, such as HER2, FRα, and TROP-2, and summarizes preclinical and clinical trial data on related ADC drugs in endometrial cancer. We also discuss the toxicity of ADC drugs. Most adverse events arise from cytotoxic components such as microtubule inhibitors and topoisomerase inhibitors. The ocular toxicity may be mainly related to off-target effects of MMAF/DF4 payloads. Interstitial lung disease (ILD) is a serious adverse event, mainly caused by antibodies, and most of them are grade 1-2 toxicity. Among them, anti-HER2 ADC induced interstitial pneumonia is commonly dose dependent. Moreover, we identified potential new targets for endometrial cancer treatment and explored strategies to overcome ADC resistance, such as choosing combination therapy or developing a new generation of ADC drugs. Continuous research and innovation in this field hold promise for improving the survival and overall quality of life of patients with advanced endometrial cancer.
Spatial expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and metastases: Implications for pathological and clinical management
Dernbach, Eich, Dragomir et al
Mod Pathol (2025)
Abstract: Muscle-invasive bladder cancer (MIBC) presents significant treatment challenges. Antibody-drug conjugates (ADCs) targeting HER2, TROP-2, and NECTIN4 offer promising therapeutic options. This study examined the spatial expression of HER2, TROP-2, and NECTIN4 in MIBC and metastases, their association with molecular subtypes, and clinical outcomes. Formalin-fixed, paraffin-embedded (FFPE) tissue samples from 251 MIBC patients were analyzed using immunohistochemistry and tissue microarrays (TMA). Expression patterns between the tumor front (TF) and center (TC) were compared, and statistical analyses assessed associations with molecular subtypes and clinical parameters. Additionally, 67 matched lymph node metastases and a secondary cohort comprising 16 distant metastases, including seven matched primary tumors, were examined to explore the expression patterns in advanced tumor stages. In primary tumors, HER2 was predominantly negative (83%) but showed higher positivity in the TC. TROP-2 exhibited high overall expression (58% score 3+), while NECTIN4 displayed significant heterogeneity with stronger expression in the TC. Spatial overexpression of TROP-2 and NECTIN4 at the tumor front relative to the tumor center was associated with a better disease free survival. Accurate assessment required four biopsies for HER2 and NECTIN4 and three for TROP-2. HER2 expression was associated with urothelial-like and genomically unstable molecular subtypes, whereas TROP-2 was widely expressed except in the mesenchymal-like subtype. NECTIN4 showed absence of staining in basal, mes-like and Sc/Nec-like subtypes. Paired lymph node metastases showed higher expression scores for all three markers, while distant metastases showed reduced NECTIN4 expression. Additionally, lymph node metastases revealed a considerable heterogeneity for HER2 compared to their matched primary tumors. The spatial heterogeneity of HER2, TROP-2, and NECTIN4 expression necessitates multiple biopsies, particularly from the TC, for accurate evaluation. These findings underscore the need for personalized treatment strategies in MIBC, considering the increased risk of relapse associated with HER2 and NECTIN4 overexpression in the TC. Implementing a multi-biopsy approach is critical to enhance diagnostic accuracy.Copyright © 2025. Published by Elsevier Inc.
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan
Roisman, Mann, Basel et al
Clin Lung Cancer (2025)
Abstract: Despite recent advances in immunotherapy combinations for extensive-stage small cell lung cancer (ES-SCLC), rapid disease progression following chemotherapy discontinuation remains a significant challenge. While the addition of pembrolizumab to platinum-etoposide has demonstrated a modest improvement in progression-free survival (PFS), there is an urgent need for more effective maintenance strategies. Sacituzumab govitecan (SG), an antibody-drug conjugate targeting Trop-2, has shown promising activity in pretreated ES-SCLC. This phase II study evaluates the efficacy and safety of adding SG to pembrolizumab maintenance therapy following chemoimmunotherapy induction in treatment-naïve ES-SCLC patients.In the PESGA trial, a prospective, open-label, single-arm phase II trial, patients with previously untreated ES-SCLC will receive induction therapy consisting of pembrolizumab (200 mg Q3 W) plus carboplatin (AUC 5) and etoposide (100 mg/m² Days 1-3) for 4 cycles. This will be followed by maintenance therapy combining pembrolizumab (200 mg Q3 W) with SG (10 mg/kg on Days 1 and 8 of 21-day cycles) for up to 31 cycles. The primary endpoint is PFS from the start of induction treatment. Secondary endpoints include overall survival, duration of response, and safety. Exploratory analyses will investigate molecular resistance mechanisms through sequential liquid and tissue biopsies and evaluate correlations between tumor Trop-2 expression and clinical outcomes. The study plans to enroll 21 patients over 18 months, with an estimated total study duration of 54 months. Results will be analyzed after 50% of patients have achieved PFS.The PESGA study design builds upon the KEYNOTE-604 regimen by incorporating SG into the maintenance phase, potentially addressing the challenge of early progression in ES-SCLC. The study may provide valuable insights into novel maintenance strategies and molecular mechanisms of treatment resistance in ES-SCLC.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Showing 1-4 of 355 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定